Recent vaccine technology in industrial animals

Kim, Hyunil; Lee, Yoo-Kyoung; Kang, Sang Chul; Han, Beom Ku; Choi, Ki Myung

doi:10.7774/cevr.2016.5.1.12

Cited by 17 publications

(12 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The iPED vaccine was formulated by alphavirus-based expression vector technology by using a recombinant Venezuelan equine encephalitis virus (VEE) strain TC-83 replicon to express the PEDV spike (S) glycoprotein. The recombinant VEE virus particles with encapsulated PEDV S RNA were harvested from infected Vero cells and the VEE replicon RNA expressing the S gene was recovered for use in the iPED vaccine (Kim et al, 2016). The vaccinated gilts and sows from production unit A generated low or negligible serum PEDV IgG and milk PEDV neutralizing antibody titers.…”

Section: Iga Antibodiesmentioning

confidence: 99%

Lactogenic immunity and vaccines for porcine epidemic diarrhea virus (PEDV): Historical and current concepts

et al. 2016

View full text Add to dashboard Cite

Morbidity, mortality, and loss of productivity from enteric diseases in neonatal piglets cost swine producers millions of dollars annually. In 2013-2014, the porcine epidemic diarrhea virus (PEDV) outbreak led to $900 million to $1.8 billion in annual losses to US swine producers. Passive lactogenic immunity remains the most promising and effective way to protect neonatal suckling piglets from enteric diseases like PEDV. Protecting suckling piglets through lactogenic immunity is dependent on trafficking of pathogen-specific IgA plasmablasts to the mammary gland and accumulation of secretory IgA (sIgA) antibodies in milk, defined as the gut-mammary-sIgA axis. Due to an impermeable placenta, piglets are born agammaglobulinic, and are highly susceptible to a plethora of infectious agents. They rely solely on colostrum and milk antibodies for maternal lactogenic immunity. Previous advances in the development of live and attenuated vaccines for another devastating diarrheal virus of pigs, transmissible gastroenteritis virus (TGEV), provide insights into the mechanisms of maternal immunity and piglet protection. In this chapter, we will review previous research on TGEV-induced lactogenic immunity to provide a historical perspective on current efforts for PEDV control and vaccines in the swine industry. Identifying factors that influence lactogenic immunity and the gut-mammary-sIgA axis may lead to improved vaccine regimens for PEDV and other enteric pathogens in gestating swine and improved overall herd immunity, swine health and industry productivity.

show abstract

Section: Iga Antibodiesmentioning

confidence: 99%

Lactogenic immunity and vaccines for porcine epidemic diarrhea virus (PEDV): Historical and current concepts

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Samples of the intestinal tract were stored at − 40 °C until analysis. In addition, fecal samples were collected on days 0, 4, 6,8,10,12,14,16,20,22,24,26,28,30,32,34, and 36 after immunization, and treated according to a previously described method [26]. Briefly, 0.1 g of fecal pellets were suspended in 400 μL of PBS containing 1 mmol L −1 phenylmethylsulfonyl fluoride (Sigma, USA) and 1% bovine serum albumin (BSA), and then incubated at 4 °C for 16 h. After centrifugation, the supernatants were stored at − 40 °C until use.…”

Section: Specimen Collectionmentioning

confidence: 99%

Oral recombinant Lactobacillus vaccine targeting the intestinal microfold cells and dendritic cells for delivering the core neutralizing epitope of porcine epidemic diarrhea virus

Wang

Huang

et al. 2018

Microb Cell Fact

View full text Add to dashboard Cite

BackgroundPorcine epidemic diarrhea caused by porcine epidemic diarrhea virus (PEDV) has led to serious economic losses to the swine industry worldwide. In this study, an oral recombinant Lactobacillus casei vaccine against PEDV infection targeting the intestinal microfold (M) cells and dendritic cells (DCs) for delivering the core neutralizing epitope (COE) of PEDV spike protein was developed with M cell-targeting peptide (Col) and dendritic cell-targeting peptide (DCpep). The immunogenicity of the orally administered recombinant strains was evaluated.ResultsAfter immunization, significantly higher levels of anti-PEDV specific IgG antibodies with PEDV neutralizing activity in the sera and mucosal sIgA antibodies in the tractus genitalis, intestinal mucus, and stools were detected in mice orally administered with the recombinant strain pPG-COE-Col-DCpep/L393, which expressed DCpep and Col targeting ligands fused with the PEDV COE antigen, compared to mice orally immunized with the recombinant strain pPG-COE/L393 without the DCpep and Col targeting ligands. Moreover, in response to restimulation with the PEDV COE antigen in vitro, a significant difference in splenocyte proliferation response and Th2-associated cytokine IL-4 level was observed in the group of mice orally immunized with pPG-COE-Col-DCpep/L393 (p < 0.05) compared to the groups of mice that received pPG-COE-Col/L393 and pPG-COE-DCpep/L393, respectively.ConclusionsThe intestinal M cells- and DCs-targeting oral delivery of genetically engineered Lactobacillus expressing the COE antigen of PEDV can efficiently induce anti-PEDV mucosal, humoral, and cellular immune responses via oral administration, suggesting a promising vaccine strategy against PEDV infection.Electronic supplementary materialThe online version of this article (10.1186/s12934-018-0861-7) contains supplementary material, which is available to authorized users.

show abstract

“…Not limited to the prevention of infectious diseases, vaccination strategies have recently been used as therapy for processes such as allergies, autoimmune diseases, and cancer [2–4]. Current vaccines rely mostly on inactivated pathogens or bacterial toxins, although problems related to the lack of purity, and thus safety, remain a challenge to overcome [1–2]. Recent research focused on the development of vaccines based on purified protein subunits, recombinant proteins, synthetic peptides and nucleic acids [1, 2, 4].…”

Section: Introductionmentioning

confidence: 99%

“…Current vaccines rely mostly on inactivated pathogens or bacterial toxins, although problems related to the lack of purity, and thus safety, remain a challenge to overcome [1–2]. Recent research focused on the development of vaccines based on purified protein subunits, recombinant proteins, synthetic peptides and nucleic acids [1, 2, 4]. However, the higher purity of these novel antigens makes them poorly immunogenic requiring administration of adjuvants to help generating effective and robust immune responses [5, 6].…”

Section: Introductionmentioning

confidence: 99%

In Vitro Evaluation of the Biological Responses of Canine Macrophages Challenged with PLGA Nanoparticles Containing Monophosphoryl Lipid A

et al. 2016

View full text Add to dashboard Cite

Poly (lactic-co-glycolic acid) nanoparticles (PLGA NPs) have been considerably studied as a promising biodegradable delivery system to induce effective immune responses and to improve stability, safety, and cost effectiveness of vaccines. The study aimed at evaluating early inflammatory effects and cellular safety of PLGA NPs, co-encapsulating ovalbumin (PLGA/OVA NPs), as a model antigen and the adjuvant monophosphoryl lipid A (PLGA/MPLA NPs) as an adjuvant, on primary canine macrophages. The PLGA NPs constructs were prepared following the emulsion-solvent evaporation technique and further physic-chemically characterized. Peripheral blood mononuclear cells were isolated from canine whole blood by magnetic sorting and further cultured to generate macrophages. The uptake of PLGA NP constructs by macrophages was demonstrated by flow cytometry, transmission electron microscopy and confocal microscopy. Macrophage viability and morphology were evaluated by trypan blue exclusion and light microscopy. Macrophages were immunophenotyped for the expression of MHC-I and MHC-II and gene expression of Interleukin-10 (IL-10), Interleukin-12 (IL-12p40), and tumor necrosis factor alpha (TNF-α) were measured. The results showed that incubation of PLGA NP constructs with macrophages revealed effective early uptake of the PLGA NPs without altering the viability of macrophages. PLGA/OVA/MPLA NPs strongly induced TNF-α and IL-12p40 expression by macrophages as well as increase relative expression of MHC-I but not MHC-II molecules. Taken together, these results indicated that PLGA NPs with addition of MPLA represent a good model, when used as antigen carrier, for further, in vivo, work aiming to evaluate their potential to induce strong, specific, immune responses in dogs.

show abstract

Recent vaccine technology in industrial animals

Cited by 17 publications

References 23 publications

Lactogenic immunity and vaccines for porcine epidemic diarrhea virus (PEDV): Historical and current concepts

Lactogenic immunity and vaccines for porcine epidemic diarrhea virus (PEDV): Historical and current concepts

Oral recombinant Lactobacillus vaccine targeting the intestinal microfold cells and dendritic cells for delivering the core neutralizing epitope of porcine epidemic diarrhea virus

In Vitro Evaluation of the Biological Responses of Canine Macrophages Challenged with PLGA Nanoparticles Containing Monophosphoryl Lipid A

Contact Info

Product

Resources

About